HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 10, October 2018 – Next-generation biosensors - Transforming the delivery of healthcare       » China tops world in alcohol-related deaths       » First China-developed drug for colorectal cancer approved in China       » World's first shrimp genome may reveal why females are superior       » Tetris-like program could speed breast cancer detection       » Wearable patch to monitor blood pressure inside body      
EYE ON CHINA
Chinese stent for heart disease reported safe in European patients
The Firehawk stent is safe and effective across a broad spectrum of patients and lesion complexity

A stent for treating coronary artery disease, known as the Firehawk, that was invented by researchers in Shanghai has been found safe and effective in European patients.

In a clinical trial involving 1,653 patients in Europe at 21 sites between December 2015 and October 2016, no significant differences were observed in the stent when compared with the global-standard product, the Xience stent, by healthcare company Abbott. Both are drug-delivering stents that are coated with medication.

A stent is a device that expands inside a blocked artery to keep it open so that blood can flow through.

Data observed 12 months after implantation of both the Firehawk and the Xience stent showed only a slight difference in indicators for cardiac arrest, myocardial infarction and the stent thrombosis rate. The rate of revascularisation was lower in the Firehawk stent.

A paper about the clinical trials after the invention of the stent by Shanghai MicroPort Medical (Group) Co was published on 3 September on the website of the Lancet, a medical journal based in the United Kingdom.

The stent achieves the same level of clinical effectiveness as the best-performing drug-delivering — or drug-eluting — stents, with the lowest drug dosage so far in the world, the company said.

"The clinical trial confirms that the Firehawk stent is safe and effective across a broad spectrum of patients and lesion complexity," said the paper's lead author, Alexandra Lansky of the Yale University School of Medicine.

Zheng Ming, vice-president of clinical medical affairs at the Shanghai company, said: "The Firehawk stent solved the dilemma between the late thrombosis event weakness of the drug-eluting stents and the low efficacy of the bare metal stents — the two main categories of stents currently used worldwide. It combines the advantages of both categories: high efficacy and longterm safety."

Late thrombosis is an extremely dangerous event for such patients, and the death rate can be as high as 50 percent, doctors said.

The innovation was that the drug is eluted from laser-cut micro grooves on the abluminal side of the stent struts, the researchers said, and the surface area of all the grooves on the stent is less than 5 percent of the total surface area of the stent while the remaining 95 percent of the stent surface remains bare metal.

"The process of laser cutting involves digging nearly 600 grooves on a hard metal as thin as hair," Zheng said.

Chang Zhaohua, founder, chairman and CEO of Micro-Port, called the research a landmark, given that it is the first time that clinical data from a drug-eluting stent manufactured in China has been published in a prestigious medical journal.

"We strongly believe and expect that the Firehawk stent, which made its market debut in Chinese hospitals in 2014 and has been approved for use and marketed in 36 countries and regions, will save millions of global patients in the years to come," he said.

According to the China Cardiovascular Disease Report 2017 published by the National Center for Cardiovascular Diseases in May, there are 290 million patients in China, and they are becoming younger. The number of male patients between 35 and 44 increased by 111 percent in the past 15 years. Altogether, 750,000 intervention treatments for coronary disease were carried out that year.

Source: China Daily

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy